C J Punt

Summary

Affiliation: University Medical Centre
Country: The Netherlands

Publications

  1. ncbi Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study
    C J A Punt
    University Medical Centre, St Radboud, Nijmegen, The Netherlands
    Ann Oncol 13:81-6. 2002
  2. ncbi Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study
    Cornelis J A Punt
    Department of Medical Oncology, University Medical Center St Radboud, PO Box 9101, 6500 HB Nijmegen, Netherlands
    Lancet 360:671-7. 2002
  3. ncbi Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer
    C J A Punt
    University Medical Centre, St Radboud, Nijmegen, The Netherlands
    Ann Oncol 13:92-4. 2002
  4. ncbi Adjuvant interferon-alpha for melanoma revisited: news from old and new studies
    C J Punt
    Department of Medical Oncology, University Medical Center St Radboud Nijmegen, The Netherlands
    Ann Oncol 12:1663-6. 2001
  5. ncbi Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG)
    C J Punt
    Department of Medical Oncology, University Medical Center St Radboud, Nijmegen, The Netherlands
    Ann Oncol 12:1289-93. 2001
  6. ncbi Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors
    C J Punt
    Department of Medical Oncology, University Medical Center St Radboud, The Netherlands
    Anticancer Drugs 12:193-7. 2001
  7. ncbi Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors
    A Sparreboom
    Department of Medical Oncology, Rotterdam Cancer Institute, University Hospital Rotterdam, The Netherlands
    Clin Cancer Res 4:1915-9. 1998
  8. ncbi Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA iso
    T J de Vries
    Department of Pathology, University Hospital, Nijmegen, The Netherlands
    Melanoma Res 10:119-26. 2000
  9. ncbi Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors
    M J de Jonge
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 17:2219-26. 1999
  10. ncbi Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma
    W H Kruit
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, The Netherlands
    Br J Cancer 74:951-5. 1996

Detail Information

Publications50

  1. ncbi Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study
    C J A Punt
    University Medical Centre, St Radboud, Nijmegen, The Netherlands
    Ann Oncol 13:81-6. 2002
    ..Phase II trials have shown promising activity of 5-FU/LV/TMTX in patients with advanced colorectal cancer (ACC). This trial evaluated the effect of TMTX in combination with 5-FU/LV as first-line treatment in ACC...
  2. ncbi Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study
    Cornelis J A Punt
    Department of Medical Oncology, University Medical Center St Radboud, PO Box 9101, 6500 HB Nijmegen, Netherlands
    Lancet 360:671-7. 2002
    ..We did a randomised trial in 27 countries to determine the effect of adding edrecolomab to the combination of fluorouracil and folinic acid in these patients...
  3. ncbi Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer
    C J A Punt
    University Medical Centre, St Radboud, Nijmegen, The Netherlands
    Ann Oncol 13:92-4. 2002
    ..Therefore, an integrated analysis of survival data from the European and USA trials was performed to detect a clinically relevant difference in survival...
  4. ncbi Adjuvant interferon-alpha for melanoma revisited: news from old and new studies
    C J Punt
    Department of Medical Oncology, University Medical Center St Radboud Nijmegen, The Netherlands
    Ann Oncol 12:1663-6. 2001
    ..A trial with intermediate-dose IFNalpha is still immature. Therefore currently the routine use of IFNalpha cannot be recommended outside the scope of clinical trials...
  5. ncbi Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG)
    C J Punt
    Department of Medical Oncology, University Medical Center St Radboud, Nijmegen, The Netherlands
    Ann Oncol 12:1289-93. 2001
    ..A phase I study was initiated to investigate the toxicity, maximum tolerated dose (MTD), and pharmacokinetics of this compound when administered intravenously at a daily times five schedule once every three weeks...
  6. ncbi Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors
    C J Punt
    Department of Medical Oncology, University Medical Center St Radboud, The Netherlands
    Anticancer Drugs 12:193-7. 2001
    ..We conclude that the recommended dose of R115777 given for 28 days followed by 1-2 weeks of rest is 300 mg b.i.d. Myelosuppression is the dose-limiting toxicity...
  7. ncbi Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors
    A Sparreboom
    Department of Medical Oncology, Rotterdam Cancer Institute, University Hospital Rotterdam, The Netherlands
    Clin Cancer Res 4:1915-9. 1998
    ..The drug demonstrated peak levels at 1.2 h and an overall bioavailability of 48.6+/-17.6% (range, 24.5-80.4%), indicating significant systemic exposure to the drug, which may enable chronic oral treatment...
  8. ncbi Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA iso
    T J de Vries
    Department of Pathology, University Hospital, Nijmegen, The Netherlands
    Melanoma Res 10:119-26. 2000
    ..Taken together these results suggest that the CPT isolation method is suitable for the isolation of mononuclear cells, including melanoma cells...
  9. ncbi Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors
    M J de Jonge
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 17:2219-26. 1999
    ....
  10. ncbi Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma
    W H Kruit
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, The Netherlands
    Br J Cancer 74:951-5. 1996
    ..The 3 day schedule was associated with manageable toxicity, but yielded a moderate response rate of 20% (CI 7-43%)...
  11. ncbi Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study
    C J Punt
    Department of Medical Oncology, University Hospital Nijmegen, The Netherlands
    Br J Cancer 76:266-9. 1997
    ....
  12. ncbi FDG-PET in colorectal cancer
    Lioe Fee de Geus-Oei
    Department of Nuclear Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Cancer Imaging 6:S71-81. 2006
    ..This review aims to outline the current and future role of FDG-PET in the field of colorectal cancer...
  13. ncbi Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer
    C J Punt
    Department of Medical Oncology, University Hospital Nijmegen, The Netherlands
    Br J Cancer 76:1376-81. 1997
    ..We conclude that S9788 administered at the doses and schedule used in this study results in relevant plasma concentrations in humans and can safely be administered in combination with doxorubicin...
  14. ncbi Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    Jolien Tol
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 360:563-72. 2009
    ..We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer...
  15. ncbi Systemic treatment of advanced colorectal carcinoma
    Hanneke W M van Laarhoven
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Eur J Gastroenterol Hepatol 16:283-9. 2004
    ..Preliminary results of treatment with anti-VEGF antibody in combination with 5-FU/LV have shown encouraging results...
  16. ncbi 5-FU-induced peripheral neuropathy: a rare complication of a well-known drug
    Hanneke W M van Laarhoven
    Department of Medical Oncology, University Medical Centre St Radboud, P O Box 9101, 6500HB Nijmegen, The Netherlands
    Anticancer Res 23:647-8. 2003
    ..We report a case of 5-FU-induced peripheral neuropathy in a patient with metastatic colorectal carcinoma. Discontinuation of 5-FU therapy is recommended in case of 5-FU-related neurotoxicity...
  17. ncbi Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR
    T J de Vries
    Department of Pathology, University Hospital, Nijmegen, The Netherlands
    Br J Cancer 80:883-91. 1999
    ..Use of more than one marker and repetition of the assay will increase the probability of finding positive PCR results...
  18. ncbi Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study
    S H Goey
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, The Netherlands
    Br J Cancer 72:1283-8. 1995
    ....
  19. ncbi Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis
    A Sparreboom
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, Rotterdam, The Netherlands
    Drug Metab Dispos 27:816-20. 1999
    ....
  20. ncbi Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study
    Theo J M Ruers
    Department of Surgery, Division of Surgical Oncology, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500 HB, Nijmegen, The Netherlands
    Ann Surg Oncol 14:1161-9. 2007
    ..Evidence on the efficacy over systemic chemotherapy is, however, extremely weak. In this prospective study we aim to assess the additional benefits of local tumour ablation...
  21. ncbi In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength
    Hanneke W M van Laarhoven
    Departments of Medical Oncology and Radiology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Cancer Res 63:7609-12. 2003
    ..We conclude that assessment of capecitabine metabolism in patients by (19)F MRS is a promising noninvasive tool for the prediction of its efficacy and toxicity, especially at the now currently available clinical field strength of 3 T...
  22. ncbi Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
    Jolien Tol
    Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Eur J Cancer 46:1997-2009. 2010
    ..Here we assess the predictive value of other potential relevant markers involved in the epidermal growth factor receptor (EGFR) signalling pathways for response to cetuximab-based treatment...
  23. ncbi Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
    Miriam Koopman
    Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
    Lancet 370:135-42. 2007
    ..Our aim was to investigate whether combination treatment is better than sequential administration of the same drugs in patients with advanced colorectal cancer...
  24. ncbi Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure
    Hanneke W M van Laarhoven
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Neoplasia 8:477-87. 2006
    ..In the C26a tumor line, carbogen breathing increased tumor growth delay by FU. In this study, carbogen breathing also enhanced systemic toxicity by FU...
  25. ncbi Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case
    Miriam Koopman
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands
    Dis Colon Rectum 51:1425-6. 2008
  26. ncbi Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials
    Cornelis J A Punt
    Department of Medical Oncology, Radboud University Nijmegen Medical Center, PO Box 9101 6500 HB Nijmegen, The Netherlands
    J Natl Cancer Inst 99:998-1003. 2007
    ..The proposed guidelines may add to the quality and cross-comparability of future studies of adjuvant treatments for cancer...
  27. ncbi Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy
    Hanneke W M van Laarhoven
    Department of Medical Oncology 550, University Medical Centre Nijmegen, P O Box, 9101 HB, Nijmegen, The Netherlands
    Crit Rev Oncol Hematol 56:321-43. 2005
    ..The recent introduction of clinical MR scanners with magnetic fields above 1.5 T may stimulate increased clinical use of (19)F MRS...
  28. ncbi Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review
    Jolien Tol
    Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Clin Ther 32:437-53. 2010
    ..Also reviewed are retrospective subset analyses of the effect of a KRAS mutation on the response to anti-EGFR antibodies...
  29. ncbi Current issues in the targeted therapy of advanced colorectal cancer
    Nikki Knijn
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, 6500 HB, Netherlands
    Discov Med 9:328-36. 2010
    ..We review the current status of targeted therapy and the mechanism of action of monoclonal antibodies in ACC...
  30. ncbi More is less -- combining targeted therapies in metastatic colorectal cancer
    Cornelis J A Punt
    Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Nat Rev Clin Oncol 6:731-3. 2009
    ..However, two recent phase III trials, CAIRO2 and PACCE, have shown a detrimental effect of adding an anti-EGFR antibody to standard chemotherapy plus bevacizumab. We discuss issues that may explain these unexpected results...
  31. ncbi Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
    Hester van Cruijsen
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Cancer 46:901-11. 2010
    ..Combination treatment with cediranib and gefitinib, an EGFR signalling inhibitor, was evaluated in patients with advanced solid tumours...
  32. ncbi Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041)
    Hanneke W M van Laarhoven
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 16:1315-23. 2010
    ....
  33. ncbi Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
    Joannes F M Jacobs
    Department of Medical Oncology, Laboratory of Medical Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 16:5067-78. 2010
    ..In this study we investigated whether transient monoclonal antibody-mediated depletion of CD25(high) regulatory T cells (Treg) is capable of enhancing the immunostimulatory efficacy of dendritic cell vaccines...
  34. ncbi Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate
    Dennis Vriens
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 50:1777-84. 2009
    ....
  35. ncbi Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET
    Hanneke W M van Laarhoven
    Department of Medical Oncology, University Medical Center Nijmegen, Geert Grooteplein 8, 6500 HB Nijmegen, The Netherlands
    Radiology 237:181-8. 2005
    ....
  36. ncbi Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state
    I Jolanda M de Vries
    Department of Tumor Immunology, University Medical Center Nijmegen, 6500 HB Nijmegen, The Netherlands
    Cancer Res 63:12-7. 2003
    ..Our present findings demonstrate that the ability of dendritic cells to mount a proper immune response correlates with their ability to migrate both in vitro and in vivo...
  37. ncbi Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases
    Hanneke W M van Laarhoven
    Department of Medical Oncology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    J Magn Reson Imaging 18:315-20. 2003
    ....
  38. ncbi Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer
    Hanneke W M van Laarhoven
    Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Int J Radiat Oncol Biol Phys 64:473-82. 2006
    ....
  39. ncbi A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005)
    ANNE O'DONNELL
    Clinical Pharmacology, E Block, Institute of Cancer Research, 15 Cotswold Road, Belmont, Surrey SM2 5NG, UK
    Cancer Chemother Pharmacol 51:58-66. 2003
    ..An open-label study was performed to determine the effect of renal impairment on the pharmacokinetics of 5-FU in the presence of eniluracil...
  40. ncbi Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
    Ulrich Keilholz
    Department of Medicine III, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    J Clin Oncol 23:6747-55. 2005
    ..This study was performed to determine whether interleukin-2 (IL-2) as a component of chemoimmunotherapy influences survival of patients with metastatic melanoma...
  41. ncbi A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer
    Marieke Krol
    Institute for Medical Technology Assessment, Erasmus Medical Centre, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Expert Opin Pharmacother 8:1313-28. 2007
    ..These studies are preferably performed by taking a societal perspective and including quality of life outcomes...
  42. ncbi Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3213-21. 2008
    ..We tested the hypothesis that circulating tumor cells (CTCs) could predict clinical outcome in patients with mCRC...
  43. ncbi Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    J Clin Oncol 25:1562-9. 2007
    ..In this study, we aimed to validate this finding in a large cohort of stage IV melanoma patients...
  44. ncbi CAIRO and FOCUS
    Matthew T Seymour
    Lancet 370:1904-5; author reply 1905. 2007
  45. ncbi Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group
    Geke A Hospers
    Medical Oncology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
    Ann Surg Oncol 14:2773-9. 2007
    ..We studied the maximum tolerated dose (MTD) and efficacy of oxaliplatin added to capecitabine and radiotherapy (Capox-RT) as neoadjuvant therapy for rectal cancer...
  46. ncbi Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer
    Cornelis J A Punt
    J Clin Oncol 26:1907-8; author reply 1908-9. 2008
  47. ncbi Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, 3008 AE Rotterdam, Netherlands
    Lancet 366:1189-96. 2005
    ..Our aim was, therefore, to assess the effect of two regimens of interferon of intermediate dose versus observation alone on distant metastasis-free interval (DMFI) and overall survival in such patients...
  48. ncbi Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
    Alexander M M Eggermont
    Erasmus University Medical Center, Rotterdam, Netherlands
    Lancet 372:117-26. 2008
    ..Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability...
  49. ncbi Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam
    Charlotte Van Kesteren
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands
    Invest New Drugs 23:225-34. 2005
    ..A semi-physiological model was successfully applied to describe the time course and extent of the neutropenia and thrombocytopenia after indisulam administration for four treatment schedules...
  50. ncbi Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Am J Clin Dermatol 4:531-6. 2003
    ..For now the role of interferon-alpha still remains to be determined and its use should be restricted to the setting of clinical trials...